December 5, 2025 – Innovega Inc., a leader in advanced vision-assistive and AR eyewear technology, today announced that it has contracted with a Taiwan-based pioneer in smart eyewear manufacturing, to design and engineer full-function Innovega smart glasses by the end of the first quarter of 2026.

This partnership marks a major step in Innovega’s transition from prototype development to large-scale commercialization, as the company prepares to launch its Gen I Smart Glasses designed to restore functional sight and independence for people living with significant vision loss.

“This is a defining moment for Innovega,” said Steve Willey, Co-Founder and CEO of Innovega. “We’ve spent years refining our technology through clinical testing and real-world feedback. This partnership allows us to take the next step, producing best of breed commercial-grade systems that meet the quality, reliability, and performance standards our patients deserve.”

The new design and engineering team brings deep expertise in optics, micro-displays, and AR wearables, having developed products for global technology leaders across Asia, Europe, and North America. By combining these advanced capabilities with Innovega’s proprietary optical platform and patent portfolio, the partnership accelerates Innovega’s timeline to market readiness.

The company’s Gen I Smart Glasses provide users with augmented functional vision through lightweight, everyday eyewear. Designed to help individuals with low vision from conditions such as macular degeneration, diabetic retinopathy, and Stargardt’s disease, the system enhances real-world imagery with customizable digital overlays, improving clarity, contrast, and confidence in daily life.

The announcement follows Innovega’s recent participation in GITEX Global 2025 in Dubai, where the leadership team, including Willey, Bambo Sofola (former Microsoft executive and Innovega’s Director of Global Strategy), and Vijay Raghavan (Innovega Board Member and former Microsoft Controller) presented the company’s vision to international investors and institutional partners.

With more than 295 million people worldwide living with moderate to severe vision impairment, Innovega’s mission extends beyond technology to delivering unprecedented independence to the low vision community.

About Innovega Inc.

Innovega Inc. is a U.S.-based technology company developing advanced vision-assistive and AR eyewear designed to restore functional sight for individuals with vision loss. Its patented system combines lightweight smart glasses with optional contact lenses to deliver both full-field real-world vision and digital clarity simultaneously. Backed by more than 75 global patents and validated through independent clinical trials, Innovega is redefining the future of vision technology.

San Diego, CA – Innovega Inc., a leader in next-generation eyewear for individuals with severe visual impairments, today announced the appointment of Bambo Sofola, former General Manager at Microsoft, to its Board of Advisors. In this role, Mr. Sofola will bring his expertise to help shape the company’s Global Strategy and Business Development initiatives.

Sofola brings decades of experience in international leadership and market development. At Microsoft, he drove business expansion across emerging markets including the Middle East, Africa, India, and Southeast Asia—regions that also represent some of the world’s largest populations of people living with vision loss.

At Innovega, Sofola will help chart the company’s expansion into these same regions, ensuring that communities most in need of vision-restoring solutions are central to the company’s global growth strategy.

“Bambo’s leadership in international business development is a tremendous asset for Innovega,” said Steve Willey, CEO of Innovega. “His track record of scaling innovation into diverse global markets, combined with his personal passion for accessibility, will help us reach millions of people worldwide who are underserved by current vision technologies.”

Sofola’s appointment underscores Innovega’s two-phase strategy: first, launch in developed markets with established distribution systems, and then scale globally into underserved regions where access to effective, dignified solutions has historically been limited.

“Joining Innovega is both an honor and an opportunity to help address one of the world’s most pressing health and accessibility challenges,” said Bambo Sofola. “Nearly 300 million people live with moderate to severe vision impairment globally, and the majority are in regions I’ve worked in throughout my career. I’m eager to contribute to Innovega’s mission of restoring independence and dignity to these communities.”

With more than 75 global patents, validated clinical trials, and growing momentum from patient testimonials and investor support, Innovega is positioned to deliver a transformative impact in the $50B+ vision tech and accessibility market. The addition of Sofola further strengthens the company’s leadership team as it prepares for international growth.

Innovega Inc. is pioneering advanced eyewear designed to restore sight for millions living with severe vision loss. Utilizing discreet smart glasses, and patented soft contact lenses, Innovega delivers a natural, high-performance visual experience that supports reading, face recognition, mobility, and independence. Headquartered in San Diego, Innovega is driven by a mission to merge cutting-edge technology with human-centered design, ensuring dignity and accessibility are at the core of every solution.

San Diego, CA – Innovega Inc., a developer of next-generation smart eyewear for the visually impaired, announced the appointment of Arthur Zhang, PhD, as its Chief Technology Officer (CTO). Arthur, who initially joined Innovega as interim CTO, now transitions into a full-time role to lead the company’s product roadmap and innovation strategy.

Arthur previously lead the Systems Architecture and Systems Engineering team in the Vision Products Group at Apple, where he played a pivotal role in the design and launch of the Apple Vision Pro. Following the product’s release, he sought an opportunity to continue shaping the future of wearable vision technology, but with a sharper focus on accessibility, dignity, and social good. That mission led him to Innovega.

“Arthur’s pedigree in both architecture and systems engineering is world-class, but what makes him invaluable to Innovega is his passion for applying that expertise to deliver real impact,” said Steve Willey, CEO of Innovega. “He shares our vision that smart glasses shouldn’t just be sleek and powerful, they should also change lives for the better.”

In his new role, Arthur will lead Innovega’s patient demonstration initiative, bringing a broader group of test participants into the company’s San Diego lab to collect and analyze data. These insights will help refine the company’s first commercial product, Innovega’s Gen I Smart Glasses, which aim to restore functional sight for millions living with severe vision loss.

“I’m excited to lead the technology team as we build and execute a product roadmap that will set a new standard for accessibility.” said Arthur. “Considering how functional people with low vision conditions already are, it’s going to be amazing to see what they will achieve once they can harness the power of our glasses.”

With nearly a decade at Apple, Arthur brings both the foresight to define the future of smart eyewear and the proven experience to deliver it. His leadership marks a significant milestone in Innovega’s journey from prototype to market-ready product.

Innovega Inc. is pioneering advanced eyewear designed to restore sight for millions living with severe vision loss. Utilizing discreet smart glasses, and patented soft contact lenses, Innovega delivers a natural, high-performance visual experience that supports reading, face recognition, mobility, and independence. Headquartered in San Diego, Innovega is driven by a mission to merge cutting-edge technology with human-centered design, ensuring dignity and accessibility are at the core of every solution.

Bellevue, Wash., March 21, 2022 — Innovega Inc., a developer of next-generation display eyewear for augmented reality, virtual reality (AR/VR) and Metaverse applications, today launched an online funding campaign with StartEngine, a leading equity crowdfunding platform.

Innovega has raised more than $16 million in total funding, and already closed more than $5.6 million in the first phase of this SEC-qualified Regulation A financing. Proceeds from this StartEngine campaign will fund important 2022 initiatives including FDA clinical investigations of its smart contact lens; preparation for commercial launch of combination contact lenses and display eyewear for use by the visually impaired including legally blind; expansion of Innovega’s portfolio of 54 U.S. and International patent cases; and development of product designs for follow-on applications and markets.

Innovega’s display system includes patented disposable soft smart contact lenses that are used in conjunction with its display glasses. This system is designed to meet wearers’ parallel demands for lightweight, stylish eyewear and for access to digital media that features high-resolution and panoramic field of view. This important combination is unavailable from other AR/VR displays that are typically encumbered by heavy, obtrusive headsets or limited by a narrow or lowresolution display.

Innovega’s capital efficient licensing model will enable established contact lens manufacturers to expand their product portfolio into this new category of smart lenses. Similarly, Innovega will offer to companies with global brands and distribution, the opportunity to co-develop and manufacture display eyewear that allows them to participate in what is being called the Metaverse, or Web 3.0.

“We are excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and have raised over half a billion dollars for its clients,” said CEO and Co-Founder, Steve Willey. “Innovega is at an exciting and pivotal time in its growth, as it prepares for commercialization of its first products. This new funding that we will raise with StartEngine, will fuel our success during what will be a busy and eventful next phase in our growth.”

To learn more about Innovega and the opportunity for equity investment during the current
limited-time funding round, please visit https://www.startengine.com/innovega-inc

Innovega Inc. is developing stylish, lightweight, wearable display eyewear systems that feature a high-resolution, panoramic-field-of-view for medical, consumer, and industrial application. The company is licensing its technology into the $74 billion global vision care market with a first focus on image enhancement for the visually impaired including the legally blind. Its transformative patented platform combines display eyewear with smart contact lenses to deliver broad applications for use in medicine, augmented reality and virtual reality. Innovega has been supported by the Defense Advanced Research Projects Agency, National Eye Institute of National Institutes of Health and National Science Foundation; and has received investments from strategic partners.

Offering Circular: https://www.sipc.org/
Related Risks: https://www.finra.org/

You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Clinical Results Presented at Recent American Academy of Optometry Meeting.

Bellevue, WA, November 10, 2021 (PRNewswire) — Dr. Jennifer Fogt, Associate Professor of Clinical Optometry at The Ohio State University and principal investigator for a Phase II clinical investigation of the use of Innovega Inc.’s eMacula® system, reported the clinical results of 15 normally sighted subjects tested with the eMacula system, which pairs the company’s iOptik® smart contact lenses with novel wide-field-of-view, high resolution display eyewear.

The data support that the system demonstrated positive results with normally sighted subjects fit with iOptik smart contact lenses when tested both with and without the display eyewear. The research was presented last week in a scientific paper during a meeting of the American Academy of Optometry in Boston.

Innovega’s eMacula system uses iOptik smart contact lenses and spectacle-mounted microdisplays with software to deliver separate images to each eye for binocular vision and to create 3D perception. The purpose of this study with normally sighted subjects was to evaluate the visual acuity obtained with the contact lenses compared to the best corrected visual acuity for each eye without the iOptik lenses; as well as the impact of the lenses on refractive correction, the ease of obtaining fusion of the images from two eyes, the stability of the fused image and the ease of obtaining the 3D experience.

The eMacula system evaluation was conducted with 15 fully sighted participants who were recruited from the OSU Optometry Clinic. The mean visual acuity measured with the iOptik contact lenses was slightly better than 20/20 and the subjects rated as “very good” the ease of fusing the images from the two eyes, the stability of the binocular display vision and the 3D experience.

“The results of this small clinical evaluation of the Innovega contact lens-enabled wearable display system support the potential to provide users with normal visual acuity and with the ability to experience stable binocular near-eye display vision with a 3D experience,” said Dr. Fogt.

Innovega is jointly developing display eyewear and software for the visually impaired and investing in process engineering to lower the cost of its molded soft smart contact lenses with the goal of commercializing a monthly disposable contact lens for the visually impaired and additional applications for normally sighted users.

“We are encouraged by the results of this study and we received valuable feedback for further refinements of our lens design and methods of assisting eye care practitioners in fitting the lenses,” said Dr. Jerry Legerton, Innovega Co-Founder and Chief Clinical and Regulatory Officer. “This was an excellent feasibility study to support the visual performance of the iOptik lens for regular vision correction and for viewing near-eye displays with binocular high resolution 3D content.”

Innovega Inc. is developing stylish, lightweight, wearable displays that feature a high-resolution, panoramic-field-of-view system for medical, consumer and industrial application. The company is first licensing its technology into the $74 billion global vision care market with an initial focus on image enhancement for the visually impaired. Its transformative patented platform, eMacula®, combines eyewear and iOptik® high-resolution smart contact lenses to deliver broad application in medicine, augmented reality and virtual reality. The company has been supported by the Defense Advanced Research Projects Agency (DARPA), National Eye Institute of National Institutes of Health and National Science Foundation; and received investments from strategic partners.

Innovega is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from Innovega:
https://www.seedinvest.com/innovega/

Novel Artificial Intelligence and Telemedicine Patent Application Propels Innovega into Software.

Bellevue, Wash., November 2, 2021 (PRNewswire) — Innovega’s robust portfolio of 51 patent cases now includes a new application teaching machine learning software to regulate the settings of extended reality (XR) eyewear driven by performance measurements of the user while wearing the smart glasses. The application also claims telecommunicating these performance data to healthcare professionals.

“The Innovega team is doubling down on its belief in the value of Personalized Extended Reality with our patent application for using psycho-physiological measures captured by the eyewear to change the settings of the eyewear,” shared Dr. Jerome Legerton, Innovega Co-Founder and lead inventor. “XR eyewear have great potential for monitoring health conditions including vision and visual performance, hearing, cognitive function, and psychological status. This patent application provides machine learning algorithms for regulating the settings of the XR eyewear for the vision and hearing output, and for visual, cognitive and psychological therapy by use of measured performance by the user.”

The patent application also includes telemedicine systems for communication of changes in vision, hearing, cognition and psychological measures to respective healthcare professionals. The real-time updates may be particularly useful to monitor patients suffering from progressive conditions like diabetic retinopathy, age-related macular degeneration, hearing loss and cognitive decline as well as managing some psychological conditions.

Innovega CEO and Co-Founder Steve Willey added, “The Intelligent Extended Reality Eyewear patent application is expected to provide Innovega with broad licensing opportunities to complement our smart contact lens technology and our XR hardware, gaze tracking, display technology and methods of fitting XR eyewear. We are now strengthening our position in smart glasses software with five patent cases directed toward software.”

Innovega’s 51 patent cases consist of 35 U.S. cases, including 14 issued patents; and 16 international cases, including nine issued patents protecting its iOptik® smart contact lenses and eMacula® display system.

Innovega Inc. is developing stylish, lightweight, wearable displays that feature a high-resolution, panoramic-field-of-view system for medical, consumer and industrial application. The Company is first licensing its technology into the $74 billion global vision care market with an initial focus on image enhancement for the visually impaired. Its transformative patented platform, eMacula®, combines eyewear and iOptik® high-resolution smart contact lenses to deliver broad application in medicine, augmented reality and virtual reality. The Company has been supported by the Defense Advanced Research Projects Agency (DARPA), National Eye Institute of National Institutes of Health and National Science Foundation; and received investments from strategic partners.

Innovega is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A.

Company’s first deployment of its eMacula system targets the visually impaired

Bellevue, Wash., October 26, 2021 (PRNewswire) – Based on a letter of intent (LOI), Innovega Inc. has agreed to pursue a definitive licensing agreement with one of the world’s leading providers of assistive technology to the visually impaired, including the legally blind. The LOI was coupled with a substantial investment in Innovega.

This partnership is expected to enable Innovega to successfully outsource the manufacture and distribution of the initial launch of its eMacula® system. This process of LOI, design collaboration, and launch is consistent with Innovega’s licensing model which the company believes can deliver maximum value to shareholders.

Innovega’s counterpart in the LOI operates in almost 100 countries and localizes products in more than 20 languages. The company’s name is confidential at this stage of development.

Innovega has raised more than $15 million in total funding, $3.5 million in the current SEC qualified funding round, and is accepting investments until November 12. For more information, see https://www.seedinvest.com/innovega/

Innovega Inc. is developing stylish, lightweight, wearable displays that feature a high-resolution, panoramic-field-of-view system for medical, consumer and industrial application. The Company is first licensing its technology into the $74 billion global vision care market with an initial focus on image enhancement for the visually impaired. Its transformative patented platform, eMacula®, combines eyewear and iOptik® high-resolution smart contact lenses to deliver broad application in medicine, augmented reality and virtual reality. The Company has been supported by the Defense Advanced Research Projects Agency (DARPA), National Eye Institute of National Institutes of Health and National Science Foundation; and received investments from strategic partners.

Innovega is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from Innovega:
https://www.seedinvest.com/innovega/

New resources support development for initial launch and expanded markets.

Bellevue, Wash., October 19, 2021 (PRNewswire) – Innovega Inc. is adding resources to support the development of its eMacula® full-field-of-view display eyewear system for extended reality (XR) applications including augmented, mixed and virtual reality. XR applications are forecast to redefine industries including healthcare, enterprise, public safety, defense, sports, education and gaming. The Innovega team’s first application of the eMacula technology will be to enhance the independence and freedom of the visually impaired, including legally blind patients, based on their new ability to achieve 20/20 vision.

Innovega signed a five-year lease for new facilities in San Diego that provide four times the space for its laboratory and offices. Earlier this year, Innovega added lens fabrication staff and expanded its process engineering team. Recently Innovega directed new resources to enhance its capability to demonstrate the innovation that flows from its 48 patent cases. The expansion of the facilities and the development team allows Innovega to maintain momentum on its path to deliver XR eyewear to patients, workers and consumers.

“Our expanded facilities will enable us to meet the needs of strategic partners and licensees with whom Innovega will collaborate to lead each commercial application,” explained CEO Steve Willey. “Our development status and funding success with our Regulation A campaign supports a strategy to immediately expand our facilities and team. Investments from the SeedInvest community enable us to leverage our technologies to improve independence and quality of life for the visually impaired and continue development for other user communities who have unmet needs.”

Innovega recently raised more than $3 million from more than 1,000 new shareholders.

Innovega Inc. is developing stylish, lightweight, wearable displays that feature a high-resolution, panoramic-field-of-view system for medical, consumer and industrial application. The Company is licensing its technology into the $74 billion global vision care market with a first focus on image enhancement for the visually impaired. Its transformative patented platform, eMacula®, combines eyewear and iOptik® high-resolution smart contact lenses to deliver broad application in medicine, augmented reality and virtual reality. The Company has been supported by the Defense Advanced Research Projects Agency (DARPA), National Eye Institute of National Institutes of Health and National Science Foundation; and received investments from strategic partners.

Innovega is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A.

Innovega’s new facility provides four times the space for its laboratory and offices.

Novel Systems Help Eye Care Practitioners Achieve Customization for Wearers

Bellevue, Wash., May 24, 2021 (PRNewswire) — Innovega Inc. filed four new patent applications for automated systems to enable eye care practitioners to efficiently and consistently fit contact lenses and augmented reality (AR) and virtual reality (VR) display-equipped eyewear. The four applications describe the apparatus and methods for image detection and measurements required for fitting contact lenses and eyewear. They are titled Automated contact lens design through image capture of an eye wearing a reference contact lens, Automated eyewear frame design through image capture, Contact lens and eyewear frame design using physical landmarks placed on an eye, and Automated contact lens design through image capture of an eye.

“More than 50% of Americans require prescription lenses to enjoy clear vision and more than 11% wear contact lenses,” shared Dr. Jerome Legerton, Innovega Co-Founder and lead inventor. “Most all have access to professional eye care. Innovega holds the belief that a significant percentage of AR and VR eyewear will be prescribed and dispensed by licensed eyecare professionals to manage the need for vision correction. We believe this delivery system will represent the segment we call Personalized Extended Reality, and automated fitting can reduce the amount of time for practitioners and patients to fit our iOptik® contact lenses and display eyewear.”

“There is a need to reduce the time required in prescribing contact lenses and glasses, while facilitating consistent outcomes,” noted Steve Willey, Innovega Co-Founder and CEO. “We see these systems as enabling technologies that will assist our commercial launch partners across a wide range of AR and VR applications.”

Innovega is in clinical development for its FDA market clearance for iOptik contact lenses in the US, along with seeking CE marking for the commercial launch in Europe

Innovega Inc. is developing stylish, lightweight, wearable displays that feature a high-resolution, panoramic-field-of-view system for medical, consumer and industrial application. The Company is licensing its technology into the $74 billion global vision care market with a first focus on image enhancement for the visually impaired. Its transformative patented platform, eMacula®, combines eyewear and iOptik® high-resolution smart contact lenses to deliver broad application in medicine, augmented reality and virtual reality. The Company has been supported by the Defense Advanced Innovega Inc.

Research Projects Agency (DARPA), National Eye Institute of National Institutes of Health and National Science Foundation; and received investments from strategic partners.